 Katja Kiseljak-Vassiliades
Concepts (214)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adrenocortical Carcinoma | 11 | 2023 | 47 | 6.240 |
Why?
| | Adrenal Cortex Neoplasms | 10 | 2023 | 48 | 5.170 |
Why?
| | Adenoma | 5 | 2019 | 191 | 1.610 |
Why?
| | Growth Hormone-Secreting Pituitary Adenoma | 3 | 2017 | 11 | 1.530 |
Why?
| | Pituitary Neoplasms | 7 | 2019 | 165 | 1.120 |
Why?
| | Adrenal Cortex | 3 | 2020 | 34 | 0.990 |
Why?
| | Pituitary Gland | 4 | 2018 | 163 | 0.870 |
Why?
| | Dehydroepiandrosterone | 1 | 2022 | 51 | 0.840 |
Why?
| | Disease Models, Animal | 3 | 2021 | 3730 | 0.840 |
Why?
| | Tumor Microenvironment | 4 | 2023 | 454 | 0.800 |
Why?
| | Adrenal Gland Neoplasms | 2 | 2021 | 81 | 0.760 |
Why?
| | Androgens | 1 | 2022 | 168 | 0.760 |
Why?
| | Drug Screening Assays, Antitumor | 2 | 2020 | 189 | 0.740 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2019 | 116 | 0.690 |
Why?
| | Genes, Tumor Suppressor | 3 | 2017 | 77 | 0.690 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2020 | 197 | 0.630 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 31 | 0.610 |
Why?
| | Gene Expression Regulation, Neoplastic | 8 | 2023 | 1167 | 0.610 |
Why?
| | Desmosomes | 1 | 2017 | 19 | 0.610 |
Why?
| | Receptors, Somatostatin | 1 | 2015 | 25 | 0.540 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2015 | 69 | 0.540 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 667 | 0.520 |
Why?
| | Acromegaly | 1 | 2014 | 15 | 0.500 |
Why?
| | Membrane Proteins | 2 | 2019 | 1056 | 0.500 |
Why?
| | Cell Line, Tumor | 9 | 2023 | 2851 | 0.490 |
Why?
| | Human Growth Hormone | 1 | 2014 | 37 | 0.490 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2021 | 740 | 0.490 |
Why?
| | Cadherins | 1 | 2015 | 186 | 0.490 |
Why?
| | Neurosurgical Procedures | 2 | 2018 | 164 | 0.480 |
Why?
| | Antineoplastic Agents | 3 | 2019 | 1974 | 0.430 |
Why?
| | Tumor Cells, Cultured | 3 | 2021 | 874 | 0.330 |
Why?
| | Cell Proliferation | 7 | 2023 | 2275 | 0.330 |
Why?
| | Apoptosis | 6 | 2021 | 2484 | 0.330 |
Why?
| | Mice, Nude | 2 | 2020 | 663 | 0.320 |
Why?
| | Biomarkers, Tumor | 3 | 2021 | 1059 | 0.310 |
Why?
| | Humans | 30 | 2023 | 119032 | 0.300 |
Why?
| | Immunotherapy | 2 | 2021 | 493 | 0.280 |
Why?
| | Prognosis | 3 | 2022 | 3443 | 0.280 |
Why?
| | Middle Aged | 9 | 2023 | 27627 | 0.220 |
Why?
| | Wnt Signaling Pathway | 2 | 2021 | 150 | 0.220 |
Why?
| | Luteinizing Hormone | 1 | 2023 | 173 | 0.220 |
Why?
| | Anorexia | 1 | 2022 | 18 | 0.220 |
Why?
| | Mice | 7 | 2021 | 15528 | 0.210 |
Why?
| | Cell Cycle Proteins | 2 | 2018 | 565 | 0.200 |
Why?
| | Aldosterone | 2 | 2019 | 43 | 0.200 |
Why?
| | Animals | 11 | 2023 | 33399 | 0.200 |
Why?
| | Hormone Replacement Therapy | 1 | 2022 | 80 | 0.200 |
Why?
| | Mitotane | 1 | 2020 | 6 | 0.200 |
Why?
| | Aurora Kinase A | 1 | 2021 | 52 | 0.190 |
Why?
| | Phthalazines | 1 | 2021 | 47 | 0.190 |
Why?
| | Heterografts | 1 | 2021 | 130 | 0.190 |
Why?
| | Pheochromocytoma | 1 | 2021 | 54 | 0.190 |
Why?
| | Adrenal Gland Diseases | 1 | 2020 | 7 | 0.190 |
Why?
| | Paraganglioma | 1 | 2021 | 48 | 0.190 |
Why?
| | Benzamides | 1 | 2021 | 176 | 0.190 |
Why?
| | Neuroendocrine Tumors | 1 | 2021 | 83 | 0.180 |
Why?
| | Indolizines | 1 | 2019 | 3 | 0.180 |
Why?
| | Forkhead Box Protein M1 | 1 | 2019 | 6 | 0.180 |
Why?
| | Immune System | 1 | 2021 | 181 | 0.180 |
Why?
| | Estrogens | 1 | 2022 | 329 | 0.170 |
Why?
| | Cell Cycle Checkpoints | 1 | 2019 | 87 | 0.170 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2021 | 181 | 0.170 |
Why?
| | Quinoxalines | 1 | 2019 | 62 | 0.170 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 112 | 0.170 |
Why?
| | Liver Neoplasms | 1 | 2023 | 527 | 0.170 |
Why?
| | Pituitary ACTH Hypersecretion | 1 | 2018 | 9 | 0.170 |
Why?
| | Gonadal Steroid Hormones | 1 | 2020 | 122 | 0.170 |
Why?
| | Lamin Type B | 1 | 2018 | 5 | 0.170 |
Why?
| | Neoplasms, Experimental | 1 | 2019 | 158 | 0.170 |
Why?
| | NIMA-Related Kinases | 1 | 2018 | 6 | 0.170 |
Why?
| | Gadolinium | 1 | 2019 | 79 | 0.170 |
Why?
| | Naphthyridines | 1 | 2018 | 16 | 0.160 |
Why?
| | Trans-Activators | 1 | 2021 | 373 | 0.160 |
Why?
| | Protein Kinase Inhibitors | 2 | 2015 | 811 | 0.160 |
Why?
| | Female | 9 | 2023 | 61588 | 0.160 |
Why?
| | Carcinogenesis | 1 | 2019 | 182 | 0.160 |
Why?
| | Signal Transduction | 4 | 2023 | 4713 | 0.160 |
Why?
| | Adult | 8 | 2023 | 31525 | 0.160 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2020 | 317 | 0.160 |
Why?
| | Calcium-Binding Proteins | 1 | 2019 | 217 | 0.160 |
Why?
| | Immunoblotting | 1 | 2018 | 307 | 0.160 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 156 | 0.150 |
Why?
| | Mutation | 3 | 2021 | 3457 | 0.150 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2018 | 333 | 0.150 |
Why?
| | RNA, Small Interfering | 1 | 2019 | 564 | 0.150 |
Why?
| | Germ-Line Mutation | 1 | 2018 | 134 | 0.150 |
Why?
| | Microarray Analysis | 1 | 2017 | 124 | 0.150 |
Why?
| | Mice, Inbred BALB C | 1 | 2020 | 1206 | 0.150 |
Why?
| | Immunohistochemistry | 2 | 2018 | 1691 | 0.140 |
Why?
| | Colorectal Neoplasms | 1 | 2023 | 628 | 0.140 |
Why?
| | Genomics | 1 | 2021 | 705 | 0.140 |
Why?
| | Quantitative Structure-Activity Relationship | 1 | 2015 | 13 | 0.140 |
Why?
| | Contrast Media | 1 | 2019 | 373 | 0.140 |
Why?
| | Phosphatidylethanolamines | 1 | 2016 | 66 | 0.140 |
Why?
| | Gonadotrophs | 2 | 2015 | 21 | 0.130 |
Why?
| | Transcriptome | 2 | 2021 | 756 | 0.130 |
Why?
| | Phosphatidylcholines | 1 | 2016 | 133 | 0.130 |
Why?
| | Phosphorylation | 1 | 2019 | 1634 | 0.130 |
Why?
| | Testosterone | 2 | 2023 | 351 | 0.130 |
Why?
| | Proto-Oncogene Proteins | 1 | 2018 | 618 | 0.120 |
Why?
| | Gene Expression Profiling | 2 | 2021 | 1597 | 0.120 |
Why?
| | Cell Survival | 4 | 2021 | 1047 | 0.110 |
Why?
| | Prospective Studies | 2 | 2023 | 6477 | 0.110 |
Why?
| | Veterans | 1 | 2023 | 1213 | 0.110 |
Why?
| | Hypogonadism | 1 | 2012 | 77 | 0.100 |
Why?
| | Antigens, Differentiation | 1 | 2011 | 79 | 0.100 |
Why?
| | Quality of Life | 1 | 2022 | 2369 | 0.100 |
Why?
| | Models, Molecular | 1 | 2015 | 1435 | 0.090 |
Why?
| | Neoplasm Invasiveness | 1 | 2012 | 462 | 0.090 |
Why?
| | Glycoproteins | 1 | 2012 | 319 | 0.090 |
Why?
| | Retrospective Studies | 3 | 2018 | 12990 | 0.090 |
Why?
| | Tumor Suppressor Proteins | 1 | 2011 | 289 | 0.090 |
Why?
| | Pyrazoles | 1 | 2012 | 363 | 0.080 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2010 | 193 | 0.080 |
Why?
| | Reproduction | 1 | 2010 | 189 | 0.080 |
Why?
| | Male | 8 | 2023 | 57818 | 0.080 |
Why?
| | Pyridines | 1 | 2012 | 440 | 0.080 |
Why?
| | Neoplasm Staging | 1 | 2012 | 1223 | 0.080 |
Why?
| | Insulin Resistance | 1 | 2016 | 1184 | 0.080 |
Why?
| | Magnetic Resonance Imaging | 1 | 2019 | 3175 | 0.080 |
Why?
| | Models, Biological | 2 | 2012 | 1715 | 0.080 |
Why?
| | Age Factors | 1 | 2014 | 2995 | 0.070 |
Why?
| | Neoplasms | 1 | 2021 | 2179 | 0.070 |
Why?
| | Muscle, Skeletal | 1 | 2016 | 1523 | 0.070 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2015 | 770 | 0.070 |
Why?
| | Carcinoma, Papillary | 1 | 2006 | 76 | 0.070 |
Why?
| | DNA, Neoplasm | 1 | 2006 | 154 | 0.070 |
Why?
| | Insulin | 1 | 2016 | 2170 | 0.070 |
Why?
| | Gene Silencing | 1 | 2006 | 177 | 0.070 |
Why?
| | Aged | 4 | 2023 | 19661 | 0.070 |
Why?
| | Cell Movement | 1 | 2010 | 897 | 0.070 |
Why?
| | Exercise | 1 | 2016 | 1657 | 0.070 |
Why?
| | Up-Regulation | 2 | 2021 | 872 | 0.060 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2006 | 202 | 0.060 |
Why?
| | United States | 1 | 2020 | 12557 | 0.060 |
Why?
| | Floxuridine | 1 | 2023 | 7 | 0.060 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 968 | 0.060 |
Why?
| | Triamcinolone Acetonide | 1 | 2023 | 24 | 0.060 |
Why?
| | Hepatic Artery | 1 | 2023 | 55 | 0.060 |
Why?
| | Thyroid Neoplasms | 1 | 2006 | 278 | 0.060 |
Why?
| | DNA Methylation | 1 | 2006 | 503 | 0.050 |
Why?
| | Follicle Stimulating Hormone | 1 | 2023 | 216 | 0.050 |
Why?
| | Neurons | 1 | 2010 | 1345 | 0.050 |
Why?
| | Stress, Physiological | 2 | 2015 | 415 | 0.050 |
Why?
| | Cellular Senescence | 1 | 2023 | 151 | 0.050 |
Why?
| | Aurora Kinase B | 1 | 2021 | 9 | 0.050 |
Why?
| | Chimerism | 1 | 2021 | 28 | 0.050 |
Why?
| | Lymphoid Tissue | 1 | 2021 | 65 | 0.050 |
Why?
| | Lymphocyte Subsets | 1 | 2021 | 76 | 0.050 |
Why?
| | Mice, SCID | 1 | 2021 | 333 | 0.050 |
Why?
| | Drug Synergism | 1 | 2021 | 339 | 0.050 |
Why?
| | Adrenal Cortex Hormones | 1 | 2023 | 521 | 0.040 |
Why?
| | Mice, Inbred NOD | 1 | 2021 | 574 | 0.040 |
Why?
| | Zebrafish | 1 | 2023 | 437 | 0.040 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2019 | 111 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 410 | 0.040 |
Why?
| | Pilot Projects | 1 | 2023 | 1420 | 0.040 |
Why?
| | Cell Death | 1 | 2020 | 339 | 0.040 |
Why?
| | Remission Induction | 1 | 2018 | 247 | 0.040 |
Why?
| | Postoperative Period | 1 | 2018 | 309 | 0.040 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2023 | 900 | 0.040 |
Why?
| | Cell Line | 2 | 2012 | 2707 | 0.030 |
Why?
| | Molecular Docking Simulation | 1 | 2015 | 101 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2021 | 540 | 0.030 |
Why?
| | Molecular Conformation | 1 | 2015 | 146 | 0.030 |
Why?
| | Tumor Stem Cell Assay | 1 | 2015 | 35 | 0.030 |
Why?
| | Cytoprotection | 1 | 2015 | 55 | 0.030 |
Why?
| | Gene Amplification | 1 | 2015 | 97 | 0.030 |
Why?
| | Mutant Proteins | 1 | 2015 | 100 | 0.030 |
Why?
| | Glucose Tolerance Test | 1 | 2016 | 368 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2021 | 2680 | 0.030 |
Why?
| | Cell Hypoxia | 1 | 2015 | 220 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 167 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 286 | 0.030 |
Why?
| | Indoles | 1 | 2015 | 316 | 0.030 |
Why?
| | Oxygen Consumption | 1 | 2016 | 586 | 0.030 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 246 | 0.030 |
Why?
| | Aging | 1 | 2023 | 1677 | 0.030 |
Why?
| | Phenotype | 1 | 2021 | 3004 | 0.030 |
Why?
| | Athletes | 1 | 2016 | 353 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2015 | 420 | 0.030 |
Why?
| | Binding Sites | 1 | 2015 | 1224 | 0.030 |
Why?
| | Sulfonamides | 1 | 2015 | 445 | 0.030 |
Why?
| | G2 Phase | 1 | 2012 | 33 | 0.030 |
Why?
| | Protein Structure, Tertiary | 1 | 2015 | 823 | 0.030 |
Why?
| | CpG Islands | 1 | 2012 | 119 | 0.030 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2012 | 113 | 0.030 |
Why?
| | Cytoplasm | 1 | 2012 | 269 | 0.020 |
Why?
| | Genes, p53 | 1 | 2011 | 64 | 0.020 |
Why?
| | Cell Division | 1 | 2012 | 776 | 0.020 |
Why?
| | Olfactory Pathways | 1 | 2010 | 56 | 0.020 |
Why?
| | Protein Binding | 1 | 2015 | 1975 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2012 | 544 | 0.020 |
Why?
| | Hypoxia | 1 | 2015 | 963 | 0.020 |
Why?
| | Neurogenesis | 1 | 2010 | 105 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 1012 | 0.020 |
Why?
| | DNA Damage | 1 | 2011 | 357 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2012 | 1158 | 0.020 |
Why?
| | Monocarboxylic Acid Transporters | 1 | 2006 | 22 | 0.020 |
Why?
| | Tissue Inhibitor of Metalloproteinase-3 | 1 | 2006 | 7 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 4709 | 0.020 |
Why?
| | Death-Associated Protein Kinases | 1 | 2006 | 10 | 0.020 |
Why?
| | Receptors, Retinoic Acid | 1 | 2006 | 41 | 0.020 |
Why?
| | Blood Glucose | 1 | 2016 | 1946 | 0.020 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2006 | 175 | 0.020 |
Why?
| | Cation Transport Proteins | 1 | 2006 | 99 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2006 | 190 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2018 | 9346 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 982 | 0.020 |
Why?
| | Young Adult | 1 | 2018 | 10799 | 0.010 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2016 | 2179 | 0.010 |
Why?
| | Adolescent | 1 | 2018 | 18483 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2011 | 6562 | 0.010 |
Why?
| | Disease Progression | 1 | 2006 | 2490 | 0.010 |
Why?
|
|
Kiseljak-Vassiliades's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|